Home

>

Newsroom
Press releases

Lupin Launches Suprax 400 mg Tablets in the US.

( 28 April 2008)
Lupin Ltd. (Lupin), announced today that its subsidiary, Lupin Pharmaceuticals Inc (LPI), has launched Suprax® 400 mg Tablets (Cefixime USP) in the US.
 

Full release
   

Lupin expands its product basket in Japan

( 23 April 2008)
Lupin Ltd today announced that its subsidiary in Japan, Kyowa Pharmaceutical Industry Co Ltd, (Kyowa) has received approvals for 10 products from the Ministry of Health & Labour Welfare, Japan (MHLW) and expects to launch these in July 2008 post NHI listing.
 

Full release
   

Lupin Q3 FY0708 Consolidated Net Profit up 192% to Rs. 1809 Mn

( 22 Jan 2008)
For Q3, Lupin achieved Sales of Rs. 7381 Mn (Rs. 5156 Mn). Earnings before Interest, Tax, Depreciation and Amortization was at Rs. 2604 Mn (Rs. 999 Mn), reflecting an EBITDA margin of 36% to sales. Profit before tax stood at Rs. 2329 Mn (Rs. 789 Mn), an increase of 195%. Profit after tax was at Rs. 1809 Mn (Rs. 620 Mn,), recording an increase of 192%.
 

Full release
   

Lupin gets new Pharmaceutical Research Head

( 13 Nov 2007)
In it’s intent to continually attract the best talent globally, Lupin Ltd. announced today the appointment of Ninad Deshpanday as President – Pharmaceutical Research and Development.
 

Full release
   

Lupin FY 2007-08 Q2 Consolidated Net Profit up 46% to Rs. 756 million.

( 24 Oct 2007)
Lupin Limited today reported a 35 % rise in revenues for the quarter ended September 30, 2007. Revenues grew from Rs. 4,995 mn in FY 2006-07 to Rs. 6,756 mn in FY 2007-08.
 

Full release
   

Lupin sells additional Perindopril patents to Servier

( 12 Oct 2007)
Lupin Ltd. announced that it has received Euro 20 million from Laboratoires Servier of France for the sale of additional patent rights for Perindopril.
 

Full release
   

Lupin acquires in Japan

(10 Oct 2007)
Lupin Limited announced today that it has completed arrangements to acquire a significant majority stake in Kyowa Pharmaceutical Industry Co. Ltd. (Kyowa), a leading Japanese generics company ranked amongst the top 10 Generic Companies.
 

Full release
   

Lupin acquires pharmaceutical business of Rubamin

(27 Sept 2007)
Lupin Ltd. (Lupin) announced today that it has acquired Rubamin Laboratories Ltd. (RLL), a part of the Rubamin group. The pharmaceutical business of Rubamin group was operated through its subsidiary RLL, largely engaged in the manufacture of advanced intermediates for APIs under Contract Research And Manufacturing (CRAMS) model.
 

Full release
   

Lupin wins Ramipril product patent challenge at Federal Circuit

(12 Sept 2007)
Lupin Ltd. (Lupin), today announced that the Court of Appeals for the Federal Circuit yesterday reversed a district court decision on Ramipril in its favor, finding the Aventis patent on Ramipril invalid. Aventis owns the '722 patent in question and King Pharmaceuticals markets Altace.
 

Full release
   

Lupin appoints Ramesh Swaminathan as President Finance & Planning

(13 August 2007)
Lupin Ltd. (Lupin), announced today that it has appointed Ramesh Swaminathan as President – Finance & Planning. He will be based at Lupin’s Corporate Office in Mumbai.
 

Full release
   

Lupin Receives “Best New Manufacturer of the Year” Award from AmerisourceBergen

(31 July 2007)
Lupin Ltd. (Lupin), announced today that it has received the award for “Best New Manufacturer of the Year, Generics Rx” from AmerisourceBergen, a leader in healthcare distribution in the US. The award is in recognition of Lupin’s contribution and commitment toward excellence as a Generic drug supplier in the US.
 

Full release
   

Lupin FY 2007-08 Q1 Net Profit up 55% to Rs. 784 million

(19 July 2007)
Lupin Limited today reported revenues of Rs. 6173 mn for the quarter ended June 2007, a rise of 27% from revenues of Rs. 4851 mn in corresponding period last year.
 

Full release
   

Lupin receives DCGI Approval to conduct Combined Phase IIb/III Clinical Trials for it’s herbal Psoriasis NCE

(18 July 2007)
Lupin Ltd.(Lupin), announced today that it has received approval from the Drugs Controller General (India) (DCGI) to conduct a combined Phase-IIb/III Clinical Trial for its herbal Anti-Psoriasis compound LLL-3348 (Desoris).
 

Full release
   

Lupin Receives US FDA Approval for Amlodipine

(17 July 2007)
Lupin Ltd. (Lupin), announced today that it has received approval from the US FDA for it’s Abbreviated New Drug Application (ANDA) for Amlodipine Besylate Tablets, 2.5 mg (base), 5 mg (base) and 10 mg (base). Commercial shipments of Amlodipine Besylate Tablets will commence shortly.
 

Full release
   

Lupin gets MHRA Approval for Lisinopril in UK

(2 July 2007)
Lupin Ltd. announced that it has received approval for generic Lisinopril 2.5mg, 5mg, 10mg and 20mg tablets from the UK MHRA. Lisinopril is an ACE inhibiting drug used for treating hypertension and congestive heart failure.
 

Full release
   

Lupin receives Final FDA Approval for Trandolapril

(14 June 2007)
Lupin Ltd. announced today that the US FDA has granted Final approval for the Company’s Abbreviated New Drug Application (ANDA) for Trandolapril Tablets, 1mg, 2mg and 4mg. Commercial shipments of the product have commenced.
 

Full release
   

Lupin Receives US FDA Approval for Cefadroxil Capsules

(31 May 2007)
Lupin Ltd., announced today that it has received approval from the US FDA for it’s Abbreviated New Drug Application (ANDA) for Cefadroxil Capsules 500mg. Cefadroxil, a broad spectrum antibiotic, is used to treat infections caused by various bacteria.
 

Full release
   

Lupin and Symbiotec decide not to pursue their MoU

(31 May 2007)
Lupin Ltd. (Lupin) had earlier announced that it had signed a MoU with Symbiotec Pharmalab Ltd. (Symbiotec), an Indian company focussed on steroids, for a joint venture by making an equity investment in Symbiotec for a majority stake.
 

Full release
   

Lupin receives tentative US FDA Approval for Ziprasidone

(21 May 2007)
Lupin Ltd., announced today that it has received final approval from the US FDA for it’s Abbreviated New Drug Application (ANDA) for Simvastatin Tablets 10mg, 20mg, 40mg and 80mg.
 

Full release
   

Lupin Receives US FDA Approval for Simvastatin Tablets

(15 May 2007)
Lupin Ltd., announced today that it has received tentative approval from the US FDA for it’s Abbreviated New Drug Application (ANDA) for Ziprasidone Capsules 20mg, 40mg and 60mg. Ziprasidone, an antipsychotic drug, is indicated for the treatment of schizophrenia and bipolar disorder. Given that the company filed the ANDA on the earliest possible NCE date, this ensures that there will be limited competition when the product goes generic.
 

Full release
   

DST and Lupin join hands over Migraine and Psoriasis

(27 April 2007)
Lupin Ltd. announced today that the Department of Science and Technology (DST), Government of India and Lupin have joined hands for the clinical development of Lupin’s Migraine and Psoriasis projects.
 

Full release
   

Lupin receives US FDA Approval for Novel Formulation of Suprax® Suspension

(12 April 2007)
Lupin Ltd. announced today that the U.S. Food and Drug Administration (US FDA) has approved the Company’s application for Suprax® Cefixime for oral suspension 200mg/5ml. Commercial shipments of the product have commenced.
 

Full release
   

Lupin finalizes patent sale agreement with Servier

(5 April 2007)
Further to it’s announcement on February 20th 2007, and pursuant to signing a definitive patent sale agreement, Lupin Limited announced today that the company has received Euro 20mn from Laboratoires Servier of France for the sale of certain patent applications and other related Intellectual Property for Perindopril for multiple countries.
 

Full release
   

Lupin gets Marketing Approval for Cefpodoxime Proxetil in France

(13 March 2007)
Lupin Ltd. announced today that, together with it’s French Regulatory agent Venipharm, it has received the Marketing Approval for generic Cefpodoxime Proxetil 100mg tablets in France. Cefpodoxime Proxetil is a cephalosporin antibiotic used to treat a variety of bacterial infections.
 

Full release
   

Lupin sells Intellectual Property on Perindopril to Servier

(20 Feb 2007)
Lupin Ltd. announced today that the Company has entered into an agreement with Laboratoires Servier of France for the sale of certain patent applications and other related Intellectual Property (IP) for Perindopril for multiple countries.
 

Full release
   

Lupin receives US FDA approval for Sertraline

(7 Feb 2007)
Lupin Ltd. today announced that the US FDA has approved the Company’s Abbreviated New Drug Application (ANDA) for Sertraline Hydrochloride Tablets, 25mg, 50mg and 100mg. Sertraline Hydrochloride is indicated for the treatment of major depressive disorder.
 

Full release
   

Lupin and Aspen decide not to pursue their MOU

(19 Jan 2007)
Lupin Limited had in February 2006 signed an MOU with Aspen Pharmacare Holdings Ltd., South Africa for a 50:50 Joint Venture for the development, manufacture and global marketing (except US, South Africa & India Trade) of a range of Anti-TB products.
 

Full release
   

Lupin FY 2006-07 Q3 Net Profit up by 27% at Rs.560 mn

(17 Jan 2007)
Lupin Limited reported a 15% rise in gross sales for the quarter ended December 2006. Sales grew from Rs. 4420 mn in Q3 2005-06 to Rs. 5069 mn in Q3 2006-07. The rise in gross sales for the first nine months ended December 2006 was 22% at Rs. 14986 mn up Rs. 2719 mn from Rs. 12267 mn for the corresponding period last year. During the quarter, Formulations grew by 31% taking the mix of formulations to 61% (54%) of total sales.
 

Full release
   

Lupin gets tentative US FDA approval for Sertraline

(2 Jan 2007)
Lupin Ltd. announce today that the US FDA has granted tentative approval for the Company's Abbreviated New Drug Application(ANDA) for Sertraline Hydrochloride Tablets, 25mg, 50mg, 100mg. Sertraline Hydrochloride is indicated for the treatment of major depressive disorder.
 

Full release
   

Lupin and Cornerstone End Development Agreement

(27 Dec 2006)
Lupin Ltd. and Cornerstone BioPharma, Inc, had, in May 2005, entered into an agreement to co-develop an anti-infective for the United States market. Both parties have now mutually agreed to end the co-development agreement.
 

Full release
   

Lupin's US Subsidiary and Chester Valley Pharmaceuticals decide to end promotion agreement

(25 Dec 2006)
Lupin Ltd’s subsidiary, Lupin Pharmaceuticals Inc., USA had, in March 2006, entered into an agreement with Chester Valley Pharmaceuticals in the United States to promote Atopiclair™ Nonsteroidal Cream to pediatricians.
 

Full release
   

Lupin gets tentative US FDA approval for Trandolapril

(19 Dec 2006)
Lupin Ltd., announced today that the US FDA has granted tentative approval for the Company’s Abbreviated New Drug Application (ANDA) for Trandolapril Tablets, 1mg, 2mg and 4mg. Trandolapril is indicated for the treatment of hypertension.
 

Full release
   

Lupin gets DCGI approval to conduct Phase III clinical trials for Migraine NCE.

(7 Dec 2006)
Lupin Ltd. announced that it has got approval from Drugs Controller General (India) (DCGI) to conduct Phase-III Clinical Trials for its Anti-Migraine compound LLL-2011 (Amigra).

Full release
 

Lupin FY 2006-07 Q2 Net Profit up by 29% at Rs.583 mn.

(19 Oct 2006)
Lupin Limited reported a 21% rise in sales (gross) for the quarter ended September 2006. Sales grew from Rs. 4.19 bn in Q2 2005-06 to Rs. 5.07 bn in Q2 2006-07. The rise in sales (gross) for the first half ended September 2006 was 26% at Rs. 9.92 bn up Rs. 2.07 bn from Rs. 7.85 bn for the corresponding period last year.

Full release
   

Mr. Edward R. Roberts joins Lupin Board.

(19 Oct 2006)
Lupin Limited today announced that Mr. Edward R. Roberts has
joined the Company’s Board as an Independent Director.

Full release
   

Lupin and Dafra decide not to pursue their MoU.

(30 Sept 2006)
Lupin Ltd. had, in May 2006 signed a MOU to acquire 51% equity in Artifex Finance CVA, Belgium along with its subsidiaries including Dafra Pharma Ltd.

Full release
   

Lupin gets US FDA approval for Lisinopril-HCTZ Tablets.

(28 Sept 2006)
Lupin Ltd., announced today that the US FDA has approved the Company’s Abbreviated New Drug Application (ANDA) for its Lisinopril and Hydrochlorothiazide Tablets (Lisinopril-HCTZ Tablets) in 10mg/12.5mg, 20mg/12.5mg and 20mg/25mg strengths. Lisinopril-HCTZ Tablets are indicated for the treatment of hypertension.

Full release
   

Lupin gets US FDA approval for Ceftriaxone 10gm vials.

(14 Sept 2006)
Lupin Ltd., announced today that the US FDA has approved the Company’s Abbreviated New Drug Application (ANDA) for its Ceftriaxone Injection 10 gram vials (Pharmacy bulk pack). Ceftriaxone is the generic equivalent of Rocephin® marketed by Roche.

Full release
   

Lupin receives DCGI approval to conduct Phase II Clinical Trials for Psoriasis NCE.

(26 July 2006)
Lupin Ltd announced that it has received approval from Drugs Controller General (India) (DCGI) to conduct Phase-II Clinical Trials for its Psoriasis pure compound LL-4218 (Desoside-P).

Full release
   

Lupin FY 2006-07 Q1 Sales up by 33% at Rs.4.9 bn.

(25 July 2006)
Lupin Limited reported a 33% rise in sales (gross) for the quarter ended June 2006. Sales grew from Rs.3.7 bn in Q1 2005-06 to Rs.4.9 bn in Q1 2006-07.

Full release
   

Lupin gets USFDA approval for Meloxicam.

(20 July 2006)
Lupin Ltd., announced today that the US FDA has approved the Company’s Abbreviated New Drug Application (ANDA) for Meloxicam Tablets, 7.5 mg and 15 mg, a widely used Non-Steroidal Anti-Inflammatory Drug (NSAID). Meloxicam is indicated for the relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis.

Full release
   

Lupin announces District Court Ruling on Ramipril.

(19 July 2006)
Lupin Limited. announced today that the United States District Court for the Eastern District of Virginia has issued an opinion following the completion of a trial on Sanofi-Aventis’ U.S. Patent No. 5061722 relating to Altace® (Ramipril) and found the patent to be valid.

Full release
   

Lupin Receives final approval for Quinapril Tablets.

(23 June 2006)
Lupin Pharmaceuticals, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Quinapril Tablets USP in 5 mg, 10 mg, 20 mg and 40 mg strengths.

Full release
   

Rajan Dutta joins Lupin as President, HRD.

(19 June 2006)
Mr. Rajan Dutta has joined Lupin Ltd. as President – Human Resources Development and will be based at Lupin’s Corporate Office in Mumbai.

Full release
   

Lupin to acquire 51% stake in Dafra.

(25 May 2006)
Lupin Ltd (Lupin) has signed a MoU to acquire a 51% equity in Artifex Finance CVA, Belgium, along with its subsidiaries including Dafra Pharma Ltd (Dafra), a Belgian pharmaceutical company focussed on anti-malarials.

Full release
   

Lupin joins hands with ItalFarmaco to launch Lupenox in India.

(15 May 2006)
Lupin Ltd. today announced that it signed an In-Licensing agreement with ItalFarmaco, a leading Italian pharmaceutical company. As per the Agreement, Lupin will exclusively market their cardiovascular Critical Care product, Enoxaparin Sodium Injection, in pre-filled syringes under the brand name “LUPENOX” in the Indian market.

Full release
   

Lupin gets USFDA approval for Cefdinir Suspension.

(2 June 2006)
Lupin Ltd. announced that the U.S. Food and Drug Administration (US FDA) has approved the Company’s Abbreviated New Drug Application (ANDA) for Cefdinir Suspension 125mg/5mL. Cefdinir is a third generation cephalosporin administered orally to treat a wide variety of bacterial infections.

Full release
   

Lupin Announces Final FDA Approval of Cefdinir Capsules.

(23 May 2006)
Lupin Pharmaceuticals, Inc. (LPI) has announced that it has received fianal approval from the U.S. Food & Drug Administration (FDA) for its Abbeviated New Drug Application (ANDA) for Cefdinir Capsuled, 300 mg.

Full release
   

Lupin’s US Subsidiary Enters Into Collaboration to Promote Atopiclair™ Nonsteroidal Cream to Pediatricians in the U.S.

(3 March 2006)
Lupin Pharmaceuticals, Inc. (LPI) has announced that it has entered into an agreement with Chester Valley Pharmaceuticals in the United States to promote Atopiclair™ Nonsteroidal Cream to pediatricians. Atopiclair™ Nonsteroidal Cream is the first prescription medical device authorized by the US FDA to relieve symptoms of atopic dermatitis and allergic contact dermatitis.

Full release
   

Lupin-Aspen sign Joint Venture

(27 Feb 2006)

Lupin Limited and Aspen Pharmacare Holdings Ltd., South Africa have entered into a Memorandum of Understanding for the establishment a 50:50 Joint Venture for the development, manufacture and global marketing (except US, South Africa & India Trade) of selected Anti-TB products.

Full release
   

Lupin LCTL Divestment

(27 Feb 2006)
The Board of Directors of Lupin Ltd. in its meeting approved the proposal to divest Company’s stake in Lupin Chemicals (Thailand) Ltd. (LCTL), a subsidiary in Thailand. LCTL is a joint venture Company wherein Lupin holds 420000 equity shares of Thai Baht 100 each constituting 60% of the share capital in LCTL. G. Premjee Group (GPG) of Thailand holds the remaining 280000 equity shares of Thai Baht 100 each constituting 40%.

Full release
   

Lupin to Reorganise Sale Structure for Suprax

(21 Feb 2006)
Lupin Ltd. reported that owing to the encouraging trend seen in the sales of its Suprax® brand in the US market, Lupin Pharmaceutical Inc (LPI); a wholly owned subsidiary of the Company, is reorganizing its sales structure. The sales force currently contracted through Ventiv Health US Sales LLC will be internalized at the beginning of the next quarter.

Full release
   

Lupin Receives US FDA Approval For Cefprozil Suspension

(20 Dec 2005)

Lupin Ltd. today announced that it has received US FDA approval for its Abbreviated New Drug Application (ANDA) for Cefprozil Oral Suspension, 125 mg/5 ml and 250 mg/5 ml. Cefprozil is the generic equivalent of Bristol Myers Squibb’s Cefzil®. The suspension market in the US is USD 119 million as per IMS MAT June 2005 data. Earlier this month, the Company received approval from the US FDA for Cefprozil tablets.

Full release
   

Lupin receives US FDA approval for Cefprozil Tablets

(09 Dec 2005)

Lupin Ltd. today announced that it has received US FDA approval for its Abbreviated New Drug Application (ANDA) for Cefprozil Tablets USP, 250 mg and 500mg. Cefprozil is the generic equivalent of Bristol Myers Squibb’s Cefzil®. The tablet market in the US is USD 117 million as per IMS MAT June 2005 data.

Full release
   

Lupin Limited places US $ 100 million Foreign Currency Convertible Bonds

(07 Dec 2005)

Lupin Limited has successfully launched and priced an accelerated zero coupon US$ 100 million (US $ one hundred million) Foreign Currency Convertible Bonds (FCCB) offering.

Full release
   

Lupin receives USFDA approval for Cephalexin Capsules

(01 Dec 2005)

Lupin Ltd announced that it has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Cephalexin Capsules USP 250 mg and 500 mg. The US market for Cephalexin Capsules is estimated at USD 80 million.

Full release
   

Lupin Receives Approval For Conducting Phase II Trials For LLL-3348 (Desoris)

(28 Nov 2005)

Lupin Ltd. announced today that it has received approval for conducting phase II clinical trials of its Investigation New Drug candidate LLL-3348 (Desoris) from the Drug Controller General of India (DCGI). Desoris is proposed for the treatment of moderate to severe chronic stable plaque-type psoriasis.

Full release
   

Lupin has entered into an agreement with GSK Philippines

(24 Oct 2005)

Lupin Limited (India) has entered into an agreement with GSK Philippines whereby Lupin will manufacture and supply the 4 & 2 Drug FDCs to GSK Philippines for marketing in Philippines. The FDC Combinations of TB drugs are based on WHO dosing guidelines.

Full release
   

Lupin Q2FY06 Net Profit Soars 158% to Rs. 452 million

(19 Oct 2005)

Lupin Limited today reported a 158 per cent rise in net profits for the quarter ended September 30, 2005 at Rs. 452 mn, up from Rs. 175 mn in the corresponding period last year.

Full release
   

Dr. Vijay Kelkar and Mr. R A Shah join Lupin Board

(19 Oct 2005)

Lupin Limited today announced that Dr. Vijay Kelkar and Mr. R A Shah have joined the company’s Board as Independent Directors.

Full release
   

Lupin – Ranbaxy Sign TB deal

(27 Sept 2005)

Lupin Limited (Lupin) and Ranbaxy Laboratories Limited (Ranbaxy), India, have entered into a licensing agreement according to which Ranbaxy will be marketing Lupin’s Tuberculosis brand in the severely affected West and North African markets. The alliance will leverage the combined strengths Lupin’s international expertise in the management of Tuberculosis (TB) and Ranbaxy’s global marketing and distribution network.

Full release
   

Lupin and Aspen Sign TB Deal

(26 Sept 2005)

Lupin Limited and Aspen Pharmacare of South Africa have entered into an agreement to collaborate for TB related products market in the Republic of South Africa. The agreement involves cooperation in the areas of technology, manufacture and marketing. The arrangement would leverage the considerable expertise in technology that Lupin has in the area of cures for TB and Aspen’s considerable marketing / technical capabilities. The current market size for TB drugs in South Africa is estimated at approx. USD 15 Million on per annum.

Full release
   

DSM Anti-Infectives India And Lupin Enter Into A Strategic Cooperation For Cephalosporins

(02 Sept 2005)

DSM Anti-Infectives India Ltd. and Lupin Limited have entered into a supply and marketing agreement for a strategic cooperation in the cephalosporins segment.

Full release
   

Lupin receives USFDA approval for Cephalexin Oral Suspension

(18 Aug 2005)

Lupin Ltd today announced that it has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Cephalexin for Oral Suspension USP, 125 mg/5 ml and 250 mg/5 ml.

Full release
   

ICRA assigns A1+ rating to short term debt programme of Lupin

(10 Aug 2005)

ICRA has upgraded the rating for the Company’s Short Term Debt (including Commercial Paper) programme of Rs. 400 millions from A1 to “A1+” (pronounced A one plus). The rating “A1+” is the highest credit quality rating assignable by ICRA for short-term debt.

Full release
   

Lupin enters into a co-operation agreement with Kyowa for Japanese market

(8 Aug 2005)

Lupin Limited and Kyowa Pharmaceutical Industry Co. Ltd., Japan announced today that they have entered into agreements through which the two will cooperate to market finished formulations in Japan.

Full release
   

Lupin Q1 FY06 Net Profit doubles to Rs. 432 million

(2 Aug 2005)

  • Gross Sales up 21% to Rs. 3.66 billion
  • Export revenue growth of 30%, mainly driven by advanced markets
  • EBITDA up 81% at Rs. 748 million
  • Net profit at Rs. 432 million, up 109%

Full release
   

Lupin launches Ceftriaxone vials in the US market

(21 July 2005)

Lupin Ltd announced that it has launched Ceftriaxone vials for injection in the US market. Ceftriaxone is the generic equivalent of Rocephin® marketed by Roche. As per MAT May 2005 IMS data, the U.S. market size for Ceftriaxone was at $ 756 million.

Full release
   

Lupin’s Goa Non Cephalosporin Oral Dosage Facility Inspected By USFDA

(08 July 2005)

Lupin Ltd today announced that its Non Cephalosporin oral dosage facility located at Verna, Goa has sailed through US FDA inspection without any 483’s. The facility, commissioned in March 2004 was set up to enable Lupin’s foray in non-cephalosporin oral dosage forms for advanced markets.

Full release
   

Lupin FY 05 Net Sales up 4% at Rs. 11,611 mn

(20 May 2005)

  • Domestic revenues at Rs. 6,097 mn (Rs. 5,425 mn) – up 12%
  • API Exports to advanced markets at Rs.1,830 mn (Rs. 1,556 mn) – up 18%
  • 14 ANDAs and 15 DMFs filed with USFDA
  • Four COS and two EDMF filed for Europe
  • R&D spend increases to 6.9% of net sales
  • Developing and Licensing deal signed with Cornerstone BioPharma, Inc for NDDS system for anti-infective product

Full release
   

Lupin Pharmaceuticals, Inc. and Cornerstone BioPharma, Inc.Enter Co-Promotion Agreement for Suprax®

(27 Jan 2005)

Lupin today announced that its wholly owned subsidiary - Lupin Pharmaceuticals, Inc. (LPI) has entered in an alliance with Cornerstone BioPharma, Inc. as a promotion partner in the US for its Suprax® (cefixime) antiinfective. Commencing immediately, Cornerstone’s sales force will co-promote Suprax® with a focus on primary care physicians, who were not covered by us.

Full release
   

Lupin Net Sales up 10% at Rs. 2,796 mn

(25 Jan 2005)

  • Domestic revenues at Rs.1,464 mn (Rs. 1,314 mn) – up 11%
  • API Exports to advanced markets at Rs.420 mn (Rs.334 mn) – up 26%
  • Two ANDAs and four DMFs filed with USFDA; taking the total to 10 ANDAs and 11 DMFs in the current year
  • R&D spend at Rs. 182 mn – up 83%
  • Anti-TB and anti-psoriasis molecules enter phase I clinical trials

Full release
   

Lupin appoints Indrajit Banerjee as President – Finance and Planning

(16 Dec 2004)

Lupin Ltd today announced the joining of Mr Indrajit Banerjee as President – Finance and Planning. Mr Banerjee is a Chartered Accountant with over two decades of experience in companies like Indal and Lucent Technologies.

Full release

   

Lupin receives IND approvals for anti-TB and anti-psoriasis molecules

(02 Dec 2004)

Lupin Ltd. announced today that it has received approval from the Drug Controller General of India (DCGI) for conducting Phase I clinical trials for two of its Investigational New Drug candidates, LL 4858 (Sudoterb) and LL 4218 (Desoside-P).

Full release

   

Lupin cranks up the R&D Engine

(27 Oct 2004)

In a substantial acceleration of its R&D programme, Lupin Limited has filed six Abbreviated New Drug Applications (ANDAs) and five Drug Master Files (DMFs) in the quarter ending 30 September 2004. This brings the total number of ANDAs filed during fiscal 2004-05 to eight. Lupin already has five ANDAs approved by the USFDA. The cumulative total of DMF filings is 21.

Full release
   

Lupin triples Research spend

(29 Jul 2004)

Lupin Limited today announced that it plans to triple its spend on
Research from Rs. 400 million in FY 2003-04 to Rs. 1.20 billion in FY 2004-05.

Full release
   

Lupin and Ind-Swift launch new anti-diarrhoeal drug

(9 Jun 2004)

Pharma major Lupin Limited and Ind-Swift Limited have launched Nitazoxanide, an anti-diarrhoeal/anthelmintic for the first time in India under the brand names Nizonide and Netazox respectively.

Full release
   

Lupin FY 2003-04 revenue up 22% at Rs 12.3 billion

(28 Apr 2004)

Lupin Ltd today announced that the net profit (before extraordinary items) for the year ended 31 March 2004 was up 100% at Rs 1,460 million as against Rs731 million a year ago. Profit before tax (before extraordinary items) was at Rs1,996 million (Rs971 million), up 106%. Increased revenues from exports resulted in the gross revenue during this period increasing by 22% at Rs 12,327 million, as against Rs10,000 million a year ago. Revenues from the advanced markets (API and finished products), which now represent 19% of the total sales, more than doubled to Rs2,289 million (Rs1,088 million). Net profit after extraordinary items provided for in quarter two stands at Rs 951 million.

Full release
 

Lupin receives INDA approval for psoriasis oral treatment

(22 Apr 2004)

Lupin Limited has got the approval for the commencement of Phase I clinical trial of its Investigational New Drug candidate LLL-3348 (Desoris) from the Drug Controller General of India (DCGI). Desoris is orally bioavailable and proposed for the treatment of chronic stable plaque type psoriasis.

Full release

 

Archives
   
 

 
 © Lupin Ltd